Business
How Many Billions Will Big Pharma Lose If Cannabis Gets Legalized?
This is the first study to ever assess the impact of marijuana on the pharmaceutical industry, regardless of patient or product type.
Each time a single person chooses to medicate with marijuana products instead of pharmaceutical drugs, it’s one big step for the legal cannabis industry and dollars lost for Big Pharma.
Ever since cannabis legalization began to take traction in the United States, Big Pharma has felt the looming threat. Slowly, biotech firms began to develop not just in the US but abroad as well, focusing on how to utilize the health benefits of the cannabis plant and translate it into safe, effective medicine that has successfully treated many conditions with no side effects — something Big Pharma has failed at doing. To add insult to injury, cannabis has also been effective at treating the opioid epidemic which is caused by medications developed by them.
Now, a new study has found that Big Pharma loses billions of dollars when states legalize marijuana. The peer-reviewed study, entitled “US Cannabis Laws Projected To Cost Generic And Brand Pharmaceutical Firms Billions”, analyzed how publicly traded pharmaceutical firms fared after adult-use or medical marijuana laws were enacted by states. According to Ziemowit Bednarek, California Polytechnic State University’s Finance Department, together with Sarah Stith, pharmaceutical stocks were worth 1.5-2% lower in only 10 days following cannabis legalization.

It solidifies other studies demonstrating how access to legal marijuana reduces consumption of fatal and addictive opioids. However, this is also the first study to ever assess the impact of marijuana on the pharmaceutical industry, regardless of patient or product type.
The study’s authors also predicted an 11% drop in pharmaceutical sales if cannabis were ever federally legal, which would cost them billions. They also acknowledge the fact that people are substituting marijuana for conventional drugs even if the industry is still working on dosage guidelines, coverage from health insurance, and standardization issues.
“Currently, cannabis patients and their providers have little information to guide them towards the most effective treatment for their condition. The future of cannabis medicine lies in understanding the prevalence and effects of the plants’ components beyond THC and CBD and identifying ways to categorize cannabis by measurable characteristics that are known to yield specific effects,” explains Stith. She also goes on to explain that in their findings, branded pharmaceutical drug companies were affected more than generic firms, likely because of the competitive impact.
The authors concluded by saying that pharmaceutical manufacturers can benefit from this by investing in the cannabis landscape instead of fighting them.
If You Can’t Beat Them, Join Them
There have been numerous cases of Big Pharma lobbying against the cannabis industry. One of the most notorious cases was that of Insys Therapeutics, a firm based out of Arizona, who was found to have spent $500,000 to a group called Arizonans for Responsible Drug Policy, which was established to try and fight Proposition 205 back in 2016. Prop 205 was the voter initiative that legalized marijuana in Arizona.
It’s no surprise why: Insys Therapeutics back then was responsible for just one product: Subsys, a sublingual spray made out of fentanyl, an extremely strong opioid that has taken thousands of lives. “Insys Therapeutics made $62 million in net revenue on Subsys fentanyl sales in the first quarter of this year, representing 100 percent of the companies earnings,” reported The Washington Post.
More recently, a group called the Community Anti-Drug Coalitions of America (CADA), which has made it their mission to advocate against the federal legalization of cannabis, shut down a page on their website where they listed their partners. One of them is Pfizer, a large global pharmaceutical firm.
What makes it ironic is that in 2021, Pfizer inked a joint deal with Arena Pharmaceuticals Inc., a biotech firm that has dedicated a segment of their medications to developing cannabinoid drugs. Arena is focused on developing drugs that target the cannabinoid receptors to treat pain caused by gastrointestinal conditions. Even if Pfizer is not directly in the business of touching the plant, it doesn’t change the fact that they are trying to make money from it.

At the end of the day, Big Pharma really is in a much better position to support cannabis instead of fight back. There’s simply no competition with marijuana – a natural, affordable plant that contains hundreds of compounds, affecting people differently yet with minimal, if any, side effects. Unlike pharmaceutical medications that come with a range of undesirable side effects if they even do work on patients.
Marijuana is one plant that can be used to treat dozens of conditions: chronic pain, anxiety, insomnia, Parkinson’s disease, cancer, depression, epilepsy, and so much more. Pharmaceutical medications have tried in vain to develop drugs that would treat these same conditions, and while they worked for some, many did not find relief. Instead, patients were left broke and unable to afford expensive treatments and medications. Whereas cannabis simply works. It’s extremely powerful and that’s why pharmaceutical corporations are afraid, feeling threatened.
So threatened, in fact, that Big Pharma has been trying to copy various cannabinoids by taking advantage of its federally illegal status and instead developing synthetic cannabinoids that they can profit from. In doing so, they also control the price and release of cannabinoids. Large pharmaceutical conglomerates need to stay afloat somehow, so they must innovate and do what they can in the meantime.
But the cannabis industry has got to keep on fighting back. Let’s not lose hope that the government will finally change the federal status of marijuana in the near future.
Source: https://thefreshtoast.com/news/how-many-billions-will-big-pharma-lose-if-cannabis-gets-legalized/
Business
Alleged Crores Pharma Scam Mastermind Arrested from Surat
After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.
Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.
Fake Business Deals and Dishonoured Cheques Used in Fraud
Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.
In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”
Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.
Multiple Identities and Repeated Fraud Pattern
Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.
Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.
Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.
Multi-State Surveillance Leads to Arrest in Surat
A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.
Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.
Growing Threat of Corporate Identity Fraud
The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.
Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.
Experts Urge Stronger Due Diligence in High-Value Transactions
Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.
Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.
Business
EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices
A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.
Investigation Under Digital Markets Act Gains Momentum
The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.
Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.
Industry Groups Demand Swift Action
Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.
Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.
In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.
Google Denies Allegations
Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.
However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.
Potential Billion-Euro Penalties
If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.
Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.
Wider Implications for Big Tech
The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.
A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.
As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.
AI & Technology
Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations
Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).
The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.
Trial Push Despite Multi-Million Euro Settlement
The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.
Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.
A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.
Allegations of VAT Evasion Through Marketplace Sellers
At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.
Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.
Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.
Italian Government Named as Affected Party
In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.
Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.
Multiple Investigations Add to Pressure
The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.
Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.
In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.
Amazon Denies Allegations
Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.
Broader Impact on Europe’s Digital Economy
If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.
With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
